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ABSTRACT
This study assessed the ability of various schedules of recombinant human thrombopoietin (rhTPO) to
enhance mobilization of peripheral blood progenitor cells (PBPCs) in 134 patients with cancer undergoing
high-dose chemotherapy and autologous PBPC transplantation. Patients received the study drug on days 1, 3,
and 5 before initiation of granulocyte colony-stimulating factor (G-CSF) 10 g/kg/day on day 5 and pheresis
starting on day 9. Randomly assigned treatments on days 1, 3, and 5 were: group 1 (n27) placebo, placebo,
rhTPO 1.5 g/kg; group 2 (n27) rhTPO 1.5 g/kg, placebo, placebo; groups 3 (n28) and 4 (n22) rhTPO
0.5 g/kg on all 3 treatment days; and group 5 (n30) placebo on all 3 treatment days. After high-dose
chemotherapy and PBPC transplantation, groups 1 through 4 received rhTPO 1.5 g/kg days 0, 2, 4, and
6 with either G-CSF 5 g/kg/day (groups 1-3) or granulocyte-macrophage colony-stimulating factor 250
g/m2/day (group 4). Group 5 received placebo plus G-CSF 5 g/kg/day. The addition of rhTPO to G-CSF
increased median CD34 cell yield/pheresis in cohorts in which rhTPO was started before day 5, with higher
yields in groups 2 (2.67  106/kg) and groups 3 and 4 (3.10  106/kg) than in group 1 (1.86  106/kg) or group
5 (1.65  106/kg) (P.006 across groups). Comparing rhTPO to placebo, higher percentages of patients
achieved the minimum yield of CD34 >2  106/kg (92% v 75%; P.050) as well as the target yield of CD34
>5  106/kg (73% v 46%; P.041). rhTPO-treated patients required fewer phereses to achieve minimum
(P.011) and target (P.015) CD34 cell values. rhTPO given after transplantation did not speed platelet
recovery. No neutralizing antibodies were observed. We conclude that rhTPO can safely enhance mobilization
of PBPC, reduce the number of leukapheresis, and allow more patients to meet minimal cell yield requirements
to receive high-dose chemotherapy with PBPC transplantation.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Autologous peripheral blood progenitor cell
(PBPC) transplantation has become an important and
effective treatment modality for patients with leuke-
mias, lymphomas, multiple myeloma, and selected
high-risk solid tumors [1-7]. Hematopoietic growth
factors, including granulocyte colony-stimulating fac-
tor (G-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF), have allowed mobiliza-
tion of CD34 PBPCs into the circulation and have
improved leukapheresis yields [8-11]. Relative to
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transplantation of autologous bone marrow progeni-
tor cells, support with cytokine-mobilized PBPC has
resulted in more rapid hematologic recovery that has
reduced the morbidity and increased the safety of
high-dose chemotherapy.
For the majority of patients, administration of
G-CSF or GM-CSF promotes the mobilization of
sufﬁcient numbers of CD34 PBPCs. However, some
patients may experience inadequate mobilization and
collection of CD34 cells, with a protracted hemato-
logic recovery that may diminish the safety of high-
dose chemotherapy. Current data suggest that a
CD34 dose of 5.0  106 cells/kg at collection is
optimal and is associated with the reliable and rapid
engraftment of both neutrophils and platelets [12,13].
CD34 doses of 2.5  106 cells/kg allow safe en-
graftment, although higher doses are associated with
faster times to platelet recovery [14]. Strategies to
improve mobilization of PBPCs are needed to ensure
adequate cell yield so that more patients are eligible
for high-dose cytotoxic therapy and to decrease the
number of leukaphereses required to achieve cell yield
targets.
Thrombopoietin (TPO), the ligand for the cyto-
kine receptor c-Mpl, is a naturally occurring glycosy-
lated peptide growth factor and the primary regulator
of megakaryocytopoiesis [15]. Activation of c-Mpl
stimulates the differentiation of bone marrow stem
cells into megakaryocyte progenitor cells, promoting
megakaryocyte proliferation and maturation and in-
creasing the number of platelets in the peripheral
blood [16-20]. In preclinical models, TPO has been
shown to accelerate the reconstitution of bone mar-
row CD34 cells and to increase the number of cir-
culating PBPCs after a midlethal dose of total body
irradiation [21]. In other studies, TPO has enhanced
proliferation of early progenitor cells committed to
the erythroid and myelomonocytic lineage [22].
Recombinant human TPO (rhTPO) is a full-
length glycosylated molecule identical to endogenous
TPO [23-25]. In preclinical models of severe throm-
bocytopenia, administration of TPO before radiation
therapy and carboplatin treatment ameliorated throm-
bocytopenia [26-28]. In initial clinical studies of my-
elosuppression, a single intravenous injection of
rhTPO before chemotherapy produced a dose-related
increase in platelets that peaked after 10 to 15 days
[29]. Preliminary results from phase I studies of
rhTPO in myelosuppressive and myeloablative set-
tings indicate that rhTPO, alone and combined with
chemotherapy and G-CSF, increases the number of
progenitor and CD34cells in the peripheral blood
[30-32].
The primary goal of this study was to evaluate the
effect of combining various treatment schedules of
rhTPO with G-CSF on the mobilization of CD34
PBPCs. The study also observed the effect of rhTPO
combined with G-CSF or GM-CSF on hematopoietic
recovery after high-dose cytotoxic chemotherapy and
infusion of the cytokine-mobilized autologous PB-
PCs.
METHODS
Patients
The study enrolled patients 18 years of age with
a histologically conﬁrmed diagnosis of breast cancer,
Hodgkin’s disease, non-Hodgkin’s lymphoma, or
multiple myeloma. Patients were required to have an
Eastern Cooperative Oncology Group performance
status of 0 or 1. Exclusion criteria were abnormal liver
function (aminotransferase or bilirubin levels 2
times upper limit of normal), leukopenia (white blood
cell count3000/L), or a history of platelet or other
disorders associated with a bleeding diathesis. Patients
were also excluded if they had prior treatment with
rhTPO, mitomycin-C, or experimental drugs within 4
weeks of study drug initiation; prior high-dose che-
motherapy with PBPC transplantation; or ongoing
use of aspirin, nonsteroidal anti-inﬂammatory drugs,
or anticoagulants. Other exclusion criteria were a his-
tory of thromboembolic disease, coronary heart dis-
ease, stroke, arrhythmias, central nervous system me-
tastases, or other organ system diseases or
abnormalities that might predispose individuals to
treatment-related complications or that might affect
study outcome. All patients provided written informed
consent and all high-dose chemotherapy and PBPC
transplantation protocols were approved by the insti-
tutional review board at each participating center.
Study Design
The study was a randomized, double-blind, placebo-
controlled, multicenter trial divided into 2 phases: (1)
a mobilization phase before treatment with high-dose
chemotherapy and (2) a reconstitution phase after
high-dose chemotherapy and infusion of PBPCs (Fig-
ure 1).
Mobilization Phase. Before initiation of the mobi-
lization phase, patients were stratiﬁed based on their
risk for delayed platelet recovery (high v low) and the
individual study site’s platelet transfusion threshold
(15 000 v 20 000/L). A patient who had experi-
enced any of the following was considered to be at
high risk for delayed platelet recovery: baseline plate-
let count of 120 000/L (measured within 7 days of
initial study drug administration), 2 prior chemo-
therapy regimens, prior radiotherapy to the spine or
pelvis, or prior exposure to stem-cell toxic-agents (eg,
cisplatin, carboplatin, nitrogen mustard, melphalan,
or ﬂudarabine) [14].
Using a centralized randomization method, eligi-
ble patients were allocated into 1 of 5 treatment
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groups (Table 1) to receive different schedules of
intravenous rhTPO (Pharmacia Corporation, Pea-
pack, NJ; Genentech, Inc, South San Francisco, CA)
or placebo. Patients assigned to treatment group 1
received placebo on days 1 and 3 and a single dose of
rhTPO 1.5 g/kg on day 5. Patients in group 2 re-
ceived a single dose of rhTPO 1.5 g/kg on day 1 and
placebo on days 3 and 5. Patients in groups 3 and 4
received a single dose of rhTPO 0.5 g/kg on each of
days 1, 3, and 5. Patients in group 5 received placebo
on days 1, 3, and 5. Doses and schedules of rhTPO
administration where based on preliminary experience
acquired in phase I studies [30,31]. All patients re-
ceived daily subcutaneous injections of G-CSF (Neu-
pogen; Amgen, Thousand Oaks, CA) 10 g/kg/day
starting on day 5 until initiation of PBPC harvest on
day 9 and continuing until completion of the PBPC
harvest. The dose of G-CSF was reduced to 5 g/kg/
day if the white blood cell count exceeded 50 000/L.
Leukapheresis began 9 days after initiation of
rhTPO therapy and was to be continued until a target
CD34 cell dose of 5  106 cells/kg had been col-
lected or a maximum of 6 aphereses had been per-
formed. Leukaphereses was stopped early if the target
CD34 cell dose was achieved or if 2 successive
aphereses yielded a CD34 cell dose 0.5  106/kg
and the attempt to collect an adequate dose of CD34
cells was deemed futile. The volume of blood pro-
cessed for each patient varied between 10 L and 20 L
(at the study site’s discretion). Each site’s local labo-
ratory measured the CD34 cell dose, and this result
guided clinical practice. PBPCs were cryopreserved
and stored according to standard methods [33].
Efﬁcacy endpoints for the mobilization phase were
the average number of CD34 cells/kg collected per
leukapheresis, the proportions of patients achieving
the minimum CD34 cell dose (2.0  106/kg) and
the target CD34 cell dose (5.0  106/kg), and the
number of leukaphereses required to achieve the min-
imum and target cell numbers.
Reconstitution Phase. Patients who achieved the
minimum cumulative target (CD34 2.0  106/kg)
were eligible to receive high-dose chemotherapy with
PBPC infusion. All patients were to have begun my-
eloablative chemotherapy within 42 days of initiation
of mobilization. PBPCs were infused within 72 hours
after completion of chemotherapy. During the recon-
stitution phase, patients in groups 1 to 4 received
rhTPO 1.5 g/kg every other day for 4 doses starting
on day 0 (the day of PBPC infusion). Patients in group
5 received placebo on these days. A myeloid growth
factor, either subcutaneously administered G-CSF 5
g/kg/day (groups 1, 2, 3, and 5) or GM-CSF 250
g/m2 (group 4), was administered from day 0 until
the absolute neutrophil count (ANC) reached 1500/
L. Prophylactic platelet transfusions were adminis-
tered when the platelet count was 15 000/L or
20 000/L, depending on each site’s practice. Red
blood cells were administered as clinically indicated.
All blood products were treated with 2500 cGy of
ionizing radiation.
In the reconstitution phase, endpoints were the
number of days required to platelet independence
(deﬁned as recovery to a post-nadir platelet count of
20 000/L on 2 consecutive days without transfu-
sions and evidence that platelet counts were stable or
Figure 1. Study schema of the treatment schedule of study drug
(rhTPO or placebo) and growth factors (granulocyte colony-stim-
ulating factor [G-CSF] or granulocyte-macrophage colony-stimu-
lating factor [GM-CSF]) during stem cell mobilization and trans-
plantation. PBPC, peripheral blood progenitor cell.
Table 1. Treatment Groups
Group S
Mobilization Period Reconstitution Period
Day 1
rhTPO
Day 3 Day 5
G-CSF
Day >5
rhTPO Days
0, 2, 4, 6
CSF Day 0 to ANC
>1500/L
1 Placebo Placebo 1.5 g/kg 10 g/kg 1.5 g/kg G-CSF 5 g/kg
2 1.5 g/kg Placebo Placebo 10 g/kg 1.5 g/kg G-CSF 5 g/kg
3 0.5 g/kg 0.5 g/kg 0.5 g/kg 10 g/kg 1.5 g/kg G-CSF 5 g/kg
4 0.5 g/kg 0.5 g/kg 0.5 g/kg 10 g/kg 1.5 g/kg GM-CSF 250 g/m2
5 Placebo Placebo Placebo 10 g/kg Placebo G-CSF 5 g/kg
Abbreviations: CSF, colony stimulating factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-
stimulating factor, rhTPO, recombinant human thrombopoietin.
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rising), proportion of patients with a platelet count of
20 000/L by days 17 and 25, the total number of
platelet transfusion events and red blood cell transfu-
sions per patient from day 0 to 35, and time to post-
nadir recovery of ANC 500 and 1500/L for 2
consecutive days.
Clinical and Laboratory Assessments
Patients were monitored for potential rhTPO tox-
icities (including extreme thrombocytosis) during the
mobilization and reconstitution phases. The severity
of adverse events was graded using the National Can-
cer Institute Common Toxicity Criteria (version 1.0).
Samples for complete blood counts, white blood count
differentials, and platelet counts were measured on
each day of rhTPO or placebo administration (days 1,
3, and 5), before each apheresis during the mobiliza-
tion phase, and daily after PBPC infusion until platelet
recovery to 50 000/L during the reconstitution
phase. Serum chemistry values were monitored on day
9 during the mobilization phase and on days 0, 7, and
14 after myeloablative therapy during the reconstitu-
tion phase. In the reconstitution phase of the study,
patients who did not achieve hematologic recovery by
35 days after graft infusion (scheduled end of study)
were followed for an additional 90 days or until re-
covery. For these patients, post-study blood counts
were determined weekly.
Immunogenicity Testing
Blood samples were screened for the presence of
anti-TPO antibodies before the administration of
rhTPO in the mobilization phase of the study and on
day 35 after PBPC infusion during the reconstitution
phase. Assays for anti-TPO antibodies were con-
ducted at Genentech using a TPO receptor capture
enzyme immunoassay based on the full-length TPO
molecule. The limit of detection in this assay is ap-
proximately 150 to 200 pg/mL.
Statistical Analysis
The primary endpoint of this study was the yield
of CD34 cells per leukapheresis session. A 1-way
analysis of variance was used to compare the average
CD34 cell yield across the rhTPO treatment groups
using the F-test on log10-transformed values. Pairwise
comparisons of all 5 treatment groups were performed
using the Tukey-Kramer test. Secondary endpoints
included the number of leukapheresis required to
achieve the minimum graft (CD34  2  106/kg)
and the target grafts ( 5  106/kg) and the propor-
tion of patients who achieved the minimum graft. The
number of leukaphereses required to achieve the min-
imum graft and the target graft across the rhTPO
mobilization groups was estimated by Kaplan-Meier
methods. The homogeneity of these cumulative dis-
tribution functions among the rhTPO mobilization
groups was evaluated using the log-rank test. The
median number of leukaphereses was reported with
95% conﬁdence intervals based on the Greenwood
formula. Fisher’s exact test was used to determine the
homogeneity between the rhTPO mobilization
groups.
During the reconstitution phase, Kaplan-Meier
methods were used to analyze the cumulative distri-
bution functions for number of days from transplan-
tation to recovery of cell counts, the number of plate-
let transfusion events from day 0 post-PBPC infusion
to day 35 and the proportions of patients with delayed
recovery. The log-rank method was used to test the
homogeneity of hematologic recovery and platelet
transfusion events among the 5 treatment groups.
Similarly, Fisher’s exact test was used to test the pro-
portion of patients with delayed platelet recovery
across the groups. Pairwise comparisons of all 5 treat-
ment groups were performed using the Tukey-
Kramer test.
RESULTS
Patient Characteristics
A total of 134 patients were enrolled; approxi-
mately equal numbers of patients were randomized to
each of the 5 treatment groups (Table 2). In the
mobilization phase, the efﬁcacy of rhTPO was assess-
able for 129 of the 134 patients; 4 patients withdrew
from the study before administration of study drug
because of progressive disease, and 1 patient devel-
oped sepsis after mobilization and did not undergo
leukapheresis. Of the 129 patients who completed the
mobilization phase, 115 achieved a minimum graft
and 14 patients failed to achieve a minimum graft. In
the reconstitution phase, 3 patients who achieved a
minimum graft did not undergo transplantation be-
cause of progressive disease; the remaining 112 pa-
tients received high-dose chemotherapy and PBPC
infusion and were fully evaluable for post-transplan-
tation assessments.
The study group consisted predominantly of
women with breast cancer and a low risk for delayed
platelet recovery (Table 2). Mean age was 48.2 years
(range, 25.9-67.5 years). Fifteen patients (11%) had
1 high-risk factor for hematologic compromise, in-
cluding 2 or more prior chemotherapy regimens (7
patients), prior radiation therapy to the spine or pelvis
(6 patients), prior exposure to an alkylating agent (5
patients), or a baseline platelet count 120 000/L (1
patient). In the 112 patients completing all protocol
therapy and follow-up, the most common high-dose
chemotherapy regimen administered during the re-
constitution phase of the study was cyclophospha-
mide  thiotepa with or without another agent (n 
C. Linker et al.
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76; 68%). Other conditioning regimens included
busulfan  melphalan  thiotepa (n  15; 13%),
cyclophosphamide  paclitaxel  doxorubicin (n  9;
8%), carmustine  etoposide  cytarabine  cyclo-
phosphamide or melphalan (n  7; 6%), and thio-
tepa  carboplatin  paclitaxel or melphalan (n  5;
4%). No regimen included total body irradiation. Risk
factors and regimens used were distributed uniformly
across treatment groups.
Effect of Recombinant Human Thrombopoietin on
Peripheral Blood Progenitor Cell Mobilization
As shown in Table 3, administration of rhTPO on
day 1 only (group 2) or on days 1, 3, and 5 of the
mobilization period (group 3 and 4) increased the
average yield of CD34 cells per apheresis compared
with placebo (group 5) or late administration (group
1) (P.006 across all treatment groups). CD34 yields
appeared similar in patients who received rhTPO 1.5
g/kg on day 1 (group 2) compared with those who
received the same total dose distributed over days 1, 3,
and 5 (groups 3 and 4). There were signiﬁcant differ-
ences across the rhTPO treatment and placebo groups
in the number of leukaphereses required to achieve
the minimum graft (P.011) and target graft
(P.015). Fewer leukaphereses were required to
achieve the minimum and target grafts with the early
administration of rhTPO (groups 2 and 3  4) than
either the late administration of rhTPO (group 1) or
placebo (group 5). Figure 2 shows these results graph-
ically, depicting the frequency distributions of patients
achieving the target cell yield by leukapheresis day;
the data indicate that higher proportions of patients in
Table 2. Baseline Patient Characteristics
Characteristic
Group 1
N  27
Group 2
N  27
Group 3
N  28
Group 4
N  22
Group 5
N  30
Combined
134
Age, yr
Mean 46.3 47.6 50.7 48.6 47.7 48.2
Range 26.8–61.9 37.1–61.7 35.8–59.9 25.9–67.5 30.2–61.9 25.9–67.5
Gender, n (%)
Female 25 (93) 25 (93) 26 (93) 21 (96) 29 (97) 126 (94)
Male 2 (7) 2 (7) 2 (7) 1 (4) 1 (3) 8 (6)
Primary diagnosis, n (%)
Breast cancer 22 (82) 23 (85) 26 (93) 20 (91) 26 (87) 117 (87)
Hematologic cancer* 5 (18) 4 (15) 2 (7) 2 (9) 4 (13) 17 (13)
Risk stratum, n (%)
Low 24 (89) 25 (93) 26 (93) 19 (86) 25 (83) 119 (89)
High† 3 (11) 2 (7) 2 (7) 3 (14) 4 (17) 15 (11)
*Includes patients with non-Hodgkin’s lymphoma (n  8), Hodgkin’s disease (n  5), and multiple myeloma (n  4).
†Includes patients with baseline platelet count of120 000/L,2 prior chemotherapy regimens, prior radiotherapy to the spine or pelvis,
or prior exposure to stem-cell–toxic agents.
Table 3. Peripheral Blood Progenitor Cell Mobilization Results
Characteristic
Group 1
N  27
Group 2
N  27
Group 34
N  47
Group 5
N  28 P Value
CD34 Cells/apheresis, 106 cells/kg
Mean 2.37 3.96 3.61 2.08 .006*
Median 1.86 2.67 3.10 1.65
95% CI for median 0.68–3.18 1.30–4.69 2.11–4.02 0.58–2.35
Aphereses required to collect minimum graft
Median† 2.0 1.0 1.0 2.0 .011‡
95% CI† 1.0–2.0 NE NE 1.0–2.0
Aphereses required to collect target graft
Median† 3.0 2.0 2.0 4.0 .015§
95% CI† 2.0–4.0 2.0–4.0 2.0–3.0 3.0–NE
Patients achieving graft, n (%)
Minimum 23 (85) 26 (96) 44 (94) 21 (75) .050§
Target 18 (67) 19 (70) 37 (79) 13 (46) .041§
Abbreviations: CI, conﬁdence interval; NE, not estimable.
*Analysis of variance F-test on log10-transformed average CD34 cells/kg per apheresis.
†Based on Kaplan-Meier estimates.
‡Log-rank test on Kaplan-Meier estimates.
§Fisher exact test.
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groups 2 and 3 4 achieved the target cell dose within
1 to 2 days relative to groups 1 and 5.
Comparing rhTPO treatment with placebo, higher
percentages of patients achieved the minimum yield
(92% v 75%; P.050) and target yield of CD34
cells/kg (73% v 46%; P.041). Early administration
of rhTPO in groups 2, and 3  4 caused a higher
percentage of patients to achieve a minimum accept-
able graft relative to group 1 or group 5. The same
pattern favoring early rhTPO administration was ap-
parent when assessing the proportion of patients
achieving the target graft.
The inﬂuence of treatment and baseline factors on
the efﬁcacy of mobilization were assessed (Table 4).
Most predictive for not achieving a minimum graft
was a diagnosis of a hematologic malignancy (non-
Hodgkin’s lymphoma, Hodgkin’s disease, or multiple
myeloma) or receiving placebo.
Posttransplantation Hematologic Recovery
When analyzed in the 112 evaluable patients who
had achieved a minimum graft and received high-dose
chemotherapy and PBPC infusion (Table 5), no dif-
ferences were seen in time to platelet recovery or the
proportions of patients with delayed platelet recovery
after day 17 or day 25. All subjects received 1 plate-
let transfusion during the posttransplantation period.
As shown in Table 5, the median number of platelet
transfusions was not signiﬁcantly different across
treatment groups. Ninety-six percent of subjects (107/
112) received 1 red blood cell transfusion. The me-
dian number of red blood cell units transfused per
subject was 4.0 for rhTPO-treated patients and 3.5 for
patients receiving placebo; no signiﬁcant differences
across treatment arms were noted.
The addition of rhTPO after high-dose chemo-
therapy and PBPC infusion did not inﬂuence the time
to neutrophil recovery. Among patients treated with
G-CSF, median times to an ANC of 500/L and
1500/L were in the range of 9 to 11 days for both
endpoints in those who had received either rhTPO
(groups 1 to 3) or placebo (group 5). Patients who
received GM-CSF plus rhTPO (group 4) had a longer
time to recovery, with median times to ANC
500/L and 1500/L of 11 and 13 days, respec-
tively. As a result of the delay in recovery in patients
given GM-CSF, the log-rank tests across all treatment
arms for these endpoints were signiﬁcant.
Safety
In the mobilization phase, no signiﬁcant differ-
ence was observed in the incidence, distribution, or
severity of adverse events across the treatment groups.
Bone pain was the most frequent adverse event ob-
served during mobilization, with an incidence of 22%
(group 1), 26% (group 2), 13% (group 3  4), and
21% (group 5). Thus, the incidence of bone pain was
not higher among the rhTPO-treated patients.
During the reconstitution phase, adverse events
were typical of those usually experienced by patients
undergoing high-dose chemotherapy with PBPC sup-
port. The most common adverse events for all groups
were fever, mucositis, diarrhea, nausea and vomiting,
all occurring with an incidence 50%; the rate was
similar across the treatment groups. The rate of rash
was higher in groups 1, 2, and 3 (49%) and 4 (63%)
than in group 5 (24%). The incidence of chills and
headache was higher in groups 1 to 3 (23% and 37%,
respectively) than in group 5 (4% and 20%, respec-
Table 4. Peripheral Blood Progenitor Cell Mobilization by Patient
Characteristics
Risk Factor
Achieved Minimum Graft
Yes
N  114
No
N  15
Primary diagnosis, n (%)
Hematologic cancer* 10 (67) 5 (33)
Breast cancer 104 (91) 10 (9)
Relative risk† 3.8
Risk stratum, n (%)
High‡ 11 (79) 3 (21)
Low 103 (90) 12 (10)
Relative risk† 2.1
Treatment group, n (%)
Placebo (group 5) 21 (75) 7 (25)
rhTPO (groups 1–4) 93 (92) 8 (8)
Relative risk† 3.2
Abbreviation: rhTPO, recombinant human thrombopoietin.
*Includes patients with non-Hodgkin’s lymphoma (n  8),
Hodgkin’s disease (n  5), and multiple myeloma (n  4).
†Ratio of risk in ﬁrst category relative to risk in secondary
category.
‡Includes patients with baseline platelet count of 120 000/L,
2 prior chemotherapy regimens, prior radiotherapy to the spine or
pelvis, or prior exposure to stem-cell–toxic agents.
Figure 2. Proportion of patients achieving the target cell graft
(5.0  106 CD34 cells/kg) by treatment group and leukapheresis
day.
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tively). Frequencies of asthenia, chest pain, chills, and
dyspnea were higher in patients who received GM-
CSF in group 4 (58%, 21%, 21%, and 32%, respec-
tively) than in group 5 (32%, 4%, 4%, and 8%, re-
spectively).
Thrombotic events were reported in 2% (2/104)
of the rhTPO-treated patients and 4% (1/28) of the
placebo-treated patients during the mobilization pe-
riod and in 6% (6/94) rhTPO-treated patients and 4%
(1/25) of placebo-treated patients during the reconsti-
tution period. In 5 of 10 patients, the thrombus oc-
curred in a central venous catheter. In the remaining
5 patients, 1 had thrombosis of the right subclavian
vein during mobilization, and 4 patients had vascular
events during reconstitution, including 1 patient with
lower leg thrombophlebitis, 1 patient with a superﬁ-
cial phlebitis at an injection site, and 2 patients with
cerebrovascular accidents (1 at the onset of atrial ﬁ-
brillation and 1 in the context of multiorgan failure).
Thrombocytosis (platelet count 500 000/L)
occurred during mobilization in 19% and 15% of
patients in groups 2 and 3  4, respectively. The
platelet count was highest (median, 400 000/L) on
days 8 and 9 of the mobilization period. In groups 3
4, the platelet count also peaked (median, 360 000/
L) on day 9. In all groups, platelet counts fell during
leukapheresis.
Determinations of anti-rhTPO antibodies were
available from 113 patients at baseline and 90 patients
on day 35 following high-dose chemotherapy and
PBPC transplantation. None of the patients had evi-
dence of anti-TPO antibodies in any assay at either
time point.
DISCUSSION
Thrombopoietin is a potent stimulator of
megakaryocytopoiesis and hematopoietic progenitor
cells [34]. In this randomized, blinded, placebo-con-
trolled study, we show that rhTPO is an active PBPC-
mobilizing agent that can enhance the yield of CD34
cells and thereby increase the percentage of patients
who achieve both the minimum dose and the target
number of PBPCs needed for transplantation. Admin-
istration of rhTPO followed in sequence by G-CSF
produced nearly a 2-fold increase in median CD34
cell dose per leukapheresis compared with placebo;
this difference was statistically signiﬁcant. Most im-
portantly, the percentage of patients reaching the
minimum graft (2.0  106CD34 cells/kg) was sig-
niﬁcantly higher in rhTPO groups (96%) than in the
placebo group (75%). Likewise, the number for pa-
tients achieving the target graft (5.0  106CD34
cells/kg) was also signiﬁcantly greater with rhTPO
treatment (79% v 46%). rhTPO also signiﬁcantly re-
duced the median number of aphereses required to
achieve both a minimum graft (1 rhTPO v 2 placebo)
and target graft (2 rhTPO v 4 placebo).
We examined different schedules of intravenous
rhTPO administration for their effect on mobilizing
efﬁcacy. It appeared that early administration of
rhTPO was the most effective in stimulating mobili-
zation. The greater effect of early over late adminis-
tration of rhTPO on CD34 cell yield may be related
to the kinetics of its biologic effect in stimulating
progenitor production in the bone marrow. Several
studies have found that rhTPO has a delayed effect in
Table 5. Hematologic Recovery in Reconstitution Phase in Fully Evaluable Patients (N  112)
Characteristic
Group 1
N  22
Group 2
N  27
Group 3
N  25
Group 4
N  18
Group 5
N  20 P Value
Days to platelets >20 000/L
Median 10.5 10.0 10.0 10.0 10.0 .815*
95% CI 9.0–11.0 9.0–13.0 9.0–11.0 9.0–11.0 9.0–11.0
Proportion of patients
with delay in recovery
of platelet count to
>20 000/L, %
Day >17 9% 15% 8% 6% 10% .933†
Day >25 5% 11% 4% 0% 10% .658†
Platelet transfusion events per patient
Median 4.0 3.0 3.0 3.0 3.0 .965*
95% CI 3.0–5.0 2.0–4.0 2.0–4.0 3.0–4.0 2.0–5.0
Days to ANC > 500/L
Median 9.0 10.0 10.0 11.0 10.0 .005*
95% CI 9.0–10.0 9.0–11.0 10.0–11.0 11.0–12.0 9.0–11.0
Days to ANC > 1500/L
Median 10.0 11.0 11.0 13.0 10.5 .005*
95% CI 10.0–11.0 10.0–12.0 NE 12.0–14.0 9.0–13.0
Abbreviations: ANC, absolute neutrophil counts; CI, conﬁdence interval; NE, not estimable.
*Log-rank test on Kaplan-Meier estimates.
†Fister’s exact test on estimated recovery probabilities obtained from Kaplan-Meier estimates.
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stimulating platelet production, and the timing of
rhTPO administration may be important for optimal
biologic activity [29,34,35].
A role for administration of posttransplantation
rhTPO remains unproven. Among the 112 fully
evaluable patients who had sufﬁcient CD34 cells to
receive high-dose chemotherapy, its use did not en-
hance platelet recovery or reduce platelet transfusion
requirements. A paucity of rhTPO-responsive pro-
genitor cells coupled with elevated rhTPO levels fol-
lowing high-dose chemotherapy [36,37] or the de-
layed action of rhTPO in stimulating platelet
production [29,34,35] may be implicated as potential
reasons for these negative ﬁndings. The median 1-day
delay in neutrophil recovery associated with posttrans-
plantation use of GM-CSF in 1 of the treatment
groups in this trial is consistent with previous infor-
mation indicating slight delays in time to neutrophil
recovery in recipients of GM-CSF versus G-CSF [38].
Administration of rhTPO as a mobilizing agent
was safe. Bone pain was the most frequent adverse
event among both rhTPO-treated and control pa-
tients, but there was no apparent increase in the inci-
dence among those patients given rhTPO. In the
reconstitution phase, rash, chills, and headache were
more prominent among patients who had received
rhTPO-mobilized PBPCs and posttransplantation
rhTPO than among placebo-treated patients. Such
effects have also not been observed in patients given
rhTPO after more conventional doses of chemother-
apy without PBPC transplantation [34]. Whether
these observations are reﬂective of a unique interac-
tion among the effects of chemotherapy, rhTPO-mo-
bilized PBPCs, or posttransplantation administration
of rhTPO is not clear at this time and will require
further study. None of these reactions were severe.
Thromboembolism, while a potential concern with an
agent that can induce thrombocytosis, was not more
evident in rhTPO-treated patients than among place-
bo-treated patients. In general, the thrombotic events
that occurred were related to use of central venous
catheters or to other comorbidities.
Neutralizing antibodies that cross-reacted with
endogenous TPO have formed in both normal volun-
teers and cancer patients who received subcutaneous
injections of a truncated form of TPO (pegylated
megakaryocyte growth and differentiation factor
[PEG-rHuMGDF]) [39]. Because such antibody for-
mation was associated with clinically signiﬁcant
thrombocytopenia, development of PEG-rHuMGDF
was terminated [40]. We did not observe such anti-
bodies in this trial of full-length rhTPO. Our results
our consistent with the lack of evidence for neutraliz-
ing antibody development in past studies with full-
length rhTPO [34].
In summary, intravenous rhTPO is safe and effec-
tive in enhancing PBPC mobilization and increasing
leukapheresis efﬁciency. Mobilization of PBPC with
rhTPO plus G-CSF may permit patients who are
unable to achieve minimum or target cell yields using
G-CSF alone to undergo high-dose myeloablative
chemotherapy. However, the population of patients in
this study was predominantly at low risk for poor
mobilization. Further studies are required to evaluate
whether the addition of rhTPO will improve the out-
come for patients at high risk for poor mobilization.
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